WebObesity induces serious diseases such as diabetes and cardiovascular disease. It has been reported that obesity increases the risk of cognitive dysfunction. Cognitive dysfunction is a characteristic symptom of Alzheimer’s and Parkinson’s diseases. However, the detailed mechanisms of obesity-induced cognitive dysfunction have not yet been … WebFeb 6, 2024 · The injection is approved in combination with plasma exchange and immunosuppressive therapy for adults with acquired thrombotic thrombocytopenia purpura.
NICE guidance on caplacizumab for treating acute acquired …
WebBackground: TTP is a rare, life-threatening thrombotic microangiopathy. While daily TPE is the mainstay of therapy, some patients are refractory to treatment and acute mortality remains 10%-20% despite treatment (Scully, Br J Haematol. 2012).In the Phase 3 HERCULES trial, 3 placebo-treated patients met the definition of refractoriness versus none in the … WebSep 22, 2024 · The post-HERCULES trial (NCT02878603) ... TTP-related events occurred in 8% of patients (4/49) randomized to caplacizumab during HERCULES versus 38% (11/29) randomized to placebo. Nineteen patients had ≥1 recurrence; 13 … floating neutral vs bonded neutral generator
Caplacizumab improves outcomes in aTTP MDedge Hematology …
WebApr 21, 2024 · The efficacy and safety of caplacizumab in individuals with acquired thrombotic thrombocytopenic purpura (aTTP) have been established in the phase 2 … WebThe costimulatory CD40L–CD40 dyad plays a major role in multiple sclerosis (MS). CD40 is highly expressed on MHCII+ B cells, dendritic cells and macrophages in human MS lesions. Here we investigated ... WebApr 29, 2024 · SuperGen/Astex Pharmaceuticals has described imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives as PIM1 selective inhibitors for leukemia and prostate cancer, including SGI-1776, which failed in Phase 1 trials due to high hERG-mediated cardiotoxicity, and the PIM1/3 inhibitor SGI-9481 (Chen, L. S., et al., Blood. 2009; 114:4150 … floating news